Role of the MDM2 Promoter Polymorphism (-309T>G) in Acute Myeloid Leukemia Development

  • Published : 2015.04.14


Background: The human homologue of the mouse double minute 2 (MDM2) gene is a negative regulator of Tp53. MDM2-309T>G a functional promoter polymorphism was found to be associated with overexpression thereby attenuation of Tp53 stress response and increased cancer susceptibility. We have planned to evaluate the possible role of MDM2-309T>G polymorphism with risk and response to chemotherapy in AML. Materials and Methods: A total of 223 de novo AML cases and 304 age and sex matched healthy controls were genotyped for the MDM2-309T>G polymorphism through the tetra-primer amplification refractory mutation system (ARMS)-PCR method. In order to assess the functional relationship of -309T>G SNP with MDM2 expression level, we quantified MDM2 mRNA in 30 primary AML blood samples through quantitative RT-PCR. Both the (-309T>G) genotypes and the MDM2 expression were correlated with disease free survival (DFS) rates among patients who have achieved complete remission (CR) after first induction chemotherapy. Results: MDM2-309T>G polymorphism was significantly associated with AML development (p<0.0001). The presence of either GG genotype or G allele at MDM2-309 confered 1.79 (95% CI: 1.12-2.86; p<0.001) and 1.46 fold (95%CI: 1.14-1.86; p= 0.003) increased AML risk. Survival analysis revealed that CR+ve cases with GG genotype had significantly increased DFS rates (16months, p=0.05) compared to CR+ve TT (11 months) and TG (9 months) genotype groups. Further, MDM2 expression was also found to be significantly elevated in GG genotype patients (p=0.0039) and among CR+ve cases (p=0.0036). Conclusions: The MDM2-309T>G polymorphism might be involved in AML development and also serve as a good prognostic indicator.


  1. Barak Y, Gottlieb E, Juven-Gershon T, Oren M (1994). Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev, 8, 1739-49.
  2. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
  3. Boyd MT, Vlatkovic N, Haines DS (2000). A novel cellular protein (MTBP) binds to MDM2 and Induces a G1 arrest that is suppressed by MDM2. J Bio Chern, 275, 31883-90.
  4. Brown CY, Mize GJ, Pineda M, George DL, Morris DR (1999). Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene, 18, 5631-7.
  5. Cheng TH, Cohen SN (2007). Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops. Mol Cell Biol, 27, 111-9.
  6. Ebid GT, Sedhom IA, El-Gammal MM, Moneer MM (2012). MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia. Asian Pac J Cancer Prev, 13, 4315-20.
  7. Ellis NA, Huo D, Yildiz O, et al (2008). MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 112, 741-9.
  8. Hong Y, Miao X, Zhang X, et al (2005). The Role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res, 65, 9582-7.
  9. Lahiri DK and Nurnberger JI (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res, 19, 5444.
  10. Michael D, Oren M (2002). The p53 and Mdm2 families in cancer. Curr Opin Genet Dev, 12, 53-9.
  11. Montes de Oca Luna R, Tabor AD, Eberspaecher H, Hulboy DL, Worth LL, et al (1996). The organization and expression of the mdm2 gene. Genomics, 33, 352-7.
  12. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-3.
  13. Phillips CL, Gerbing R, Alonzo T et al (2010). MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the children's Oncology Group. Pediatr Blood Cancer, 55, 248-53.
  14. Rayburn E, Zhang R, He J, Wang H (2005). MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets, 5, 27-41.
  15. Wan Y, Wu W, Yin Z, Guan P, Zhou B (2011). MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer. 11, 208.
  16. Xiao M, Zhang L, Zhu X, et al (2010). Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer, 10, 147.
  17. Xiong X, Wang M Wang L, et al (2009). Risk of MDM2SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res, 33, 1454-8.
  18. Wan Y, Wu W, Yin Z, Guan P, Zhou B (2011). MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer. 11, 208.
  19. Yan YL, Han F, Tan WM, Wu CP, Qin X (2014). Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis. Asian Pac J Cancer Prev, 15, 6767-72.
  20. Ye Y, Li X, Yang J, et al (2013). MDM2 is a useful prognostic biomarker for resectable gastric cancer. Cancer Sci, 104, 590-98.
  21. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M (1995). A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res, 23, 2584-92.